VIVEbiotech signs three contracts for gene therapy clinical trials for 1.4 million euros

VIVEbiotech has signed three new contracts for the production of lentiviral vectors for three clinical trials for an amount of 1.4 million euros. Two of them are to supply lentiviruses to two European hospitals (one Spanish and one Swiss), and the third one to a Norwegian company.

The pathologies to be treated are two types of cancer, which will receive immunotherapy with CAR-Ts/TCRs, and a rare disease, which causes an alteration of the immune response and recurrent infections in those who suffer it. The lots of viral vectors that VIVEbiotech will produce for these three new contracts will be delivered in the last quarter of 2018 and throughout 2019.

In the case of the two types of cancer that will receive immunotherapy, the viral vectors that will be produced introduce genetic modifications in the 'T' cells of the patient's immune system so that they recognize the tumor cells and selectively destroy them.

The CEO of VIVEbiotech, Gurutz Linazasoro, has ensured that "these contracts demonstrate the recognition of the market" to the work carried out by this company and its "progressive consolidation" in the market of new therapies against cancer.

VIVEbiotech will multiply its production capacity tenfold with the construction of two new clean rooms with large-capacity bioreactors, and plans to expand its workforce by 25% next year, currently comprising 26 employees.

You can check the news in the following links:

Contact us

Mikeletegi Pasealekua 81, San Sebastián 20009, Gipuzkoa (SPAIN)